Neurodegenerative Diseases Registry

Related Clinical Trial
Optimization of Morphomer-based Alpha-synuclein PET Tracers Evaluation of [18F]APN-1607 as a PET Biomarker A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY Complex Eye Movements in Parkinson’s Disease and Related Movement Disorders tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study Application od Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) Remote Monitoring in Progressive Supranuclear Palsy (PSP) Trial of Parkinson’s And Zoledronic Acid Rho Kinase (ROCK) Inhibitor in Tauopathies – 1 UPenn Observational Research Repository on Neurodegenerative Disease Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies The MOTIVE-PSP Initiative A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP) Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Misfolded Proteins in the Skin of People With Parkinson’s Disease and Other Parkinsonism Neurodegenerative Diseases Registry Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer’s Disease, Other Dementias and Normal Controls Brain Network Activation in Patients With Movement Disorders Neurologic Stem Cell Treatment Study ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes ADDIA Proof-of-Performance Clinical Study Defining Phenotypes of Movement Disorders :Parkinson’s Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography. Gait Analysis in Neurological Disease Diagnosing Frontotemporal Lobar Degeneration Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Study of the Neural Basis of Analogical Reasoning Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Diagnostic and Prognostic Biomarkers in Parkinson Disease Tau Imaging With JNJ067 Research of Biomarkers in Parkinson Disease More Than a Movement Disorder: Applying Palliative Care to Parkinson’s Disease Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Identifying Biomarkers of Parkinson’s Disease Using Magnetic Resonance Imaging (MRI) Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Davunetide (AL-108) in Predicted Tauopathies – Pilot Study Robot Walking Rehabilitation in Parkinson’s Disease Human CNS Tau Kinetics in Tauopathies 4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2 In-Home Care for Patients With PSP and Related Disorders Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Biomarkers in Parkinsonian Syndromes Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Effects of Coenzyme Q10 in PSP and CBD 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Oxford Study of Quantification in Parkinsonism A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects The Neural Basis for Frontotemporal Degeneration Analysis of the Enteric Nervous System Using Colonic Biopsies Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy 4 Repeat Tauopathy Neuroimaging Initiative A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson’s Disease and Progressive Supranuclear Palsy. Safety Study of TPI-287 to Treat CBS and PSP Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Neuroprotection and Natural History in Parkinson’s Plus Syndromes (NNIPPS) Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism tDCS Plus Physical Therapy for Progressive Supranuclear Palsy Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Risk Factors for Progressive Supranuclear Palsy (PSP) Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy Neuropsychological Evaluation for Early Diagnosis of PSP Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer’s, Progressive Supranuclear Palsy Subjects, and Controls A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Young Plasma Transfusions for Progressive Supranuclear Palsy Study of BIIB092 in Participants With Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Deep TMS for the Treatment of Patients With Parkinson’s Disease and Progressive Supranuclear Palsy Rehabilitation in Patients With Progressive Supranuclear Palsy A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Postural Instability in Progressive Supranuclear Palsy

Brief Title

Neurodegenerative Diseases Registry

Official Title

Biomarkers in Neurodegenerative Diseases

Brief Summary

      With the increase in life expectancy of our population due to advancement of medical
      diagnosis and treatments, the incidence of age dependent neurodegenerative diseases
      increased, including Alzheimer's disease (AD), parkinsonian syndromes (PS), small vessel
      disease (SVD) and motor neuron disease (MND). In spite of the progress of knowing the
      pathogenesis of various neurodegenerative diseases at molecular and genetic level, they are
      still very incompletely understood and often cause diagnostic and therapeutic challenges to
      physicians. Due to the overlapping presentation and similar brain pathology, especially in
      the early stage of the diseases, it is difficult to differentiate idiopathic Parkinson's
      disease (iPD) from atypical parkinsonian syndromes, such as multiple system atrophy (MSA) and
      progressive supranuclear palsy (PSP). Similarly, distinguishing AD from other dementia
      syndromes including frontotemporal dementia (FTD), dementia with Lewy Bodies (DLB),
      corticobasal degeneration (CBD) and vascular dementia can be difficult. It is necessary to
      develop accurate and comprehensive diagnostic tests to properly prognosticate the diseases,
      start treatments in early stage of the diseases and maximize the accuracy of drug trials for
      more effective preventive and therapeutic measures for these neurodegenerative diseases.

      Therefore, the registry aims to generate a large database of cognitive, behavioral, lifestyle
      and psychological information of the subjects who suffered from neurodegenerative diseases,
      as well as to examine the genetic basis of neurodegenerative diseases to help decode the
      pathogenic mechanisms of the diseases. The registry may provide important information to
      understand symptom development of the neurodegenerative diseases, in which may help
      physicians to diagnose the diseases more accurately and provide better treatment plans.
    

Detailed Description

      This is a cohort study. It involves baseline, 1st follow up visit and 2nd follow up visit. At
      baseline visit, all participants will go through a list of assessments and questionnaires and
      blood taking. Follow-up visit(s) will be scheduled every one to two years, in which the same
      set of assessments and questionnaires will be administered.

        1. Clinical assessments and questionnaires

           Different clinical assessments would be administered depending on the group that the
           participant belongs to:

             -  Hoehn and Yahr Stage and the Unified Parkinson's Disease Rating Scale (UPDRS) for
                iPD, PSP and SVD patients with parkinsonism features

             -  Unified MSA Rating Scale (UMSARS) for MSA

             -  Levodopa Equivalent Dosage for medication burden for parkinsonian syndromes
                patients

             -  Amyotrophic lateral sclerosis functional rating scale revised (ALSFRS-R), body
                weight and forced vital capacity (FVC) for MND group

             -  Montreal Cognitive Assessment Hong Kong version (HK-MoCA), Olfactory Identification
                Test (OIT) and Farnsworth-Munsell 100 Hue test for all groups

           Video taking would be administered to record participants' eye movement if necessary.
           For example, video of eye movement is useful to rate MSA patients' ocular motor
           dysfunction, such as gaze-evoke nystagmus.

           Patients with parkinsonian syndromes will fill in a set of questionnaires, including
           demographic information, medical history, history and current medications, wearing-off
           questionnaire, impulsiveness questionnaire, Buss-Perry Aggression Questionnaire (BPAQ),
           rapid eye movement sleep behavior disorder questionnaire (RBDQ), Epworth Sleepiness
           Scale (ESS), Morningness-Eveningness Questionnaire (MEQ), Insomnia Severity Index (ISI),
           Beck's Scale for Suicide Ideation (BSSI), Scales for Outcomes in Parkinson's
           Disease-Autonomic questionnaire (SCOPA-AUT), Hospital Anxiety and Depression Scale
           (HADS), Patient Health Questionnaire (PHQ9), lifestyle and life history, and occupation
           history.

        2. Blood sampling Blood taking would be carried out at Prince of Wales Hospital and will be
           processed and transported to the laboratory according to standard procedure.

           Venous blood samples are collected into 6 EDTA tubes and 1 Heparin tube. The volume of
           total blood samples will not exceed 23ml. Serum is obtained within 1 hour by
           centrifugation at 3,000 rpm for 10 min and stored at -70°C until laboratory evaluation
           for proteomics, SERS and other biochemical and genetics studies.

        3. Sub-studies Selected participants in the cohort groups, especially those with early
           disease onset and/or familial cases, would proceed to sub-studies which include brain
           MRI, brain PET, lumbar puncture and/or skin biopsy. Subjects are voluntary to join one
           or more sub-studies.
    


Study Type

Observational [Patient Registry]


Primary Outcome

the score change in Unified Parkinson's Disease Rating Scale (UPDRS)


Condition

Neurodegenerative Diseases


Study Arms / Comparison Groups

 Early idiopathic Parkinson's Disease
Description:  200 patients with iPD based on Movement Disorder Society clinical diagnostic criteria for Parkinson's disease with disease onset less than 5 years

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

1400

Start Date

October 9, 2019

Completion Date

August 2024

Primary Completion Date

August 2024

Eligibility Criteria

        Inclusion Criteria:

          -  Age should be between 18-80 years old.

        Exclusion Criteria:

          -  Patients with ongoing central nervous system infection and/or acute stroke or active
             brain tumor.
      

Gender

All

Ages

18 Years - 80 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Vincent Mok, PhD, +852 2697 5027, [email protected]

Location Countries

Hong Kong

Location Countries

Hong Kong

Administrative Informations


NCT ID

NCT04472130

Organization ID

CRE-2019.371


Responsible Party

Sponsor-Investigator

Study Sponsor

Vincent Mok


Study Sponsor

Vincent Mok, PhD, Principal Investigator, Chinese University of Hong Kong


Verification Date

July 2021